Abstract
Clear cell sarcoma-like tumour of the gastrointestinal tract (CCSLGT) is a rare entity which has been recently described as late as 2003. Only around 70 cases have been reported in the English literature till date. CCSLGT is mostly seen in young adults in the late 20 s and early 30 s. CCSLGT are aggressive tumours. They are similar to the clear cell sarcoma of the soft tissue but lack melanocytic differentiation, retain neuroendocrine differentiation, and have osteoclastic giant cells. EWSR1–CREB1 fusion is characteristic of these tumours. Complete surgical excision is the best treatment option available. They have a high recurrence rate and poor prognosis. Currently, effective chemotherapy or a targeted agent is not available for the management of these tumours. Here, we describe a case of clear cell sarcoma-like tumour of jejunum encountered by us in a young man. The immunohistochemical and genetic profiling of these tumours are also discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Zambrano E, Reyes-Mugica M, Franchi A, et al. An osteoclast-rich tumour of the gastrointestinal tract with features resembling clear cell sarcoma of soft parts: reports of 6 cases of a GIST simulator. Int J Surg Pathol. 2003;11:75–81.
Sonai MK, Rastogi S, Madhusudhan KS, et al. Clear cell sarcoma like tumour of gastrointestinal tract: experience of three cases and review of literature. Indian J Pathol Microbiol. 2020;63:90–5.
Antonescu CR, Nafa K, Segal NH, et al. EWS-CREB1: a recurrent variant fusion in clear cell sarcoma–association with gastrointestinal location and absence of melanocytic differentiation. Clin Cancer Res. 2006;12:5356–62.
Askan G, Kombak FE, Seven IE, et al. Clear cell sarcoma-like tumour of the gastrointestinal tract. J Gastrointest Cancer. 2019;50:651–6.
Libertini M, Thway K, Noujaim J, et al. Clear cell sarcoma-like tumour of the gastrointestinal tract: clinical outcome and pathologic features of a molecularly characterized tertiary center case series. Anticancer Res. 2018;38:1479–83.
Wang J, Thway K. Clear cell sarcoma-like tumour of the gastrointestinal tract: an evolving entity. Arch Pathol Lab Med. 2015;139:407–12.
Yegen G, Güllüoğlu M, Mete Ö, et al. Clear cell sarcoma-like tumour of the gastrointestinal tract: a case report and review of the literature. Int J Surg Pathol. 2015;23:61–7.
Stockman DL, Miettinen M, Suster S, et al. Malignant gastrointestinal neuroectodermal tumour: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of 16 cases with a reappraisal of clear cell sarcoma-like tumours of the gastrointestinal tract. Am J Surg Pathol. 2012;36:857–68.
Thway K, Judson I, Fisher C. Clear cell sarcoma-like tumour of the gastrointestinal tract, presenting as a second malignancy after childhood hepatoblastoma. Case Rep Med. 2014;2014:1.
Subbiah V, Holmes O, Gowen K, et al. Activity of c-Met/ALK inhibitor crizotinib and multi-kinase VEGF inhibitor pazopanib in metastatic gastrointestinal neuroectodermal tumor harboring EWSR1-CREB1 fusion. Oncology. 2016;91:348–53.
Davis IJ, McFadden AW, Zhang Y, et al. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. Cancer Res. 2010;70:639–45.
Tazzari M, Palassini E, Vergani B, et al. Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report. BMC Cancer. 2015;15:58.
Stacchiotti S, Grosso F, Negri T, et al. Tumor response to sunitinib malate observed in clear-cell sarcoma. Ann Oncol. 2010;21:1130–1.
Tate JG, Bamford S, Jubb HC, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019;47:D941–7.
Lal N, Beggs AD, Willcox BE, et al. An immunogenomic stratification of colorectal cancer: implications for development of targeted immunotherapy. Oncoimmunology. 2015;4:e976052.
Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20.
Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189–99.
Johnson DB, Frampton GM, Rioth MJ, et al. Targeted next generation sequencing identifies markers of response to PD-1 blockade. Cancer Immunol Res. 2016;4:959–67.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Murugappan Nachiappan, Gangadhara Dashavara Srikantaiah and Srikanth Gadiyaram declare that they have no conflict of interest.
Human and animal rights
All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Informed Consent
nformed consent was obtained from all patients for being included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Nachiappan, M., Srikantaiah, G.D. & Gadiyaram, S. Clinical, pathological, and genetic profile of clear cell sarcoma-like tumour of jejunum: report of a rare aggressive tumour of small bowel. Clin J Gastroenterol 15, 107–111 (2022). https://doi.org/10.1007/s12328-021-01554-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12328-021-01554-9